Breaking News, Collaborations & Alliances

Beroni Signs Agreement with CDMO Genscript Biotech

To conduct further study to develop nanobody-based medical solution for COVID-19.

By: Contract Pharma

Contract Pharma Staff

Beroni Group has signed an agreement with GenScript Biotech to conduct antibody characterization and optimization for COVID-19 treatment through humanization and affinity maturation with the objective of increasing the antibody affinity to target the antigen by five to ten-fold.    Genscript will render the services based on 3 phases: (1) Perform pseudovirus neutralization assay with candidate antibody (2) Production and characterization of humanized antibodies and (3) Using PML (Precise Mutagen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters